H

Hana Pharm Co Ltd
KRX:293480

Watchlist Manager
Hana Pharm Co Ltd
KRX:293480
Watchlist
Price: 11 010 KRW -1.08% Market Closed
Market Cap: 195.6B KRW

P/E
Price to Earnings

9
Current
10.3
Median
20.5
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
9
=
Market Cap
190.5B KRW
/
Net Income
21.3B KRW
Earnings Growth PEG
KR
H
Hana Pharm Co Ltd
KRX:293480
Average P/E: 24.5
9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
66.1
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
26.2
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
19
19%
1
CH
Roche Holding AG
SIX:ROG
18.2
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
30.7
36%
0.9
CH
Novartis AG
SIX:NOVN
18.1
16%
1.1
US
Merck & Co Inc
NYSE:MRK
12.1
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
FR
Sanofi SA
PAR:SAN
20.9
28%
0.7

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
7.5
2-Years Forward
P/E
6.9
3-Years Forward
P/E
N/A